Table 10:
CATT Non-Inferiority RCT Comparisons of Bevacizumab Versus Ranibizumab for n-AMD
| CATT Comparison at Year 1 | ||||
|---|---|---|---|---|
| Group 1 | Group 2 | Δ ETDRS BCVA Letters Mean | 99.2% CI | Inferiority Comparison |
| Bevacizumab monthly | Ranibizumab monthly | –0.5 | –3.9 to 2.9 | Not inferior |
| Bevacizumab PRN | Ranibizumab PRN | –0.8 | –4.1 to 2.4 | Not inferior |
| Ranibizumab PRN | Ranibizumab monthly | –1.7 | –4.7 to 1.3 | Not inferior |
| Bevacizumab PRN | Bevacizumab monthly | –2.1 | –5.7 to 1.6 | Inferior |
| Ranibizumab PRN | Bevacizumab monthly | –1.2 | –4.5 to 2.1 | Not inferior |
| Bevacizumab PRN | Ranibizumab monthly | –2.6 | –5.9 to 0.8 | Inferior |
Abbreviations: BCVA, best corrected visual acuity; CI, confidence interval; ETDRS, Early Treatment Diabetic Retinopathy Study; PRN, pro re nata (as needed).